Patients with myelofibrosis are more likely than those with essential thrombocythemia to progress to leukemia, according to a study involving 83 individuals. Moreover, survival is extremely poor regardless of myeloproliferative neoplasm (MPN) subtype.
Participants--from the Surveillance, Epidemiology and End Results 13 database—all had MPNs that transformed to leukemia. Among the results:
- The 5-year incidence of leukemic transformation was more than 2% in males, vs slightly more than 1% in females.
- It was more than 2% in patients with myelofibrosis.
- In patients with essential thrombocythemia and polycythemia vera, the incidence was 0.37% and 0.72%, respectively.
- Patients survived a median of 2 months after leukemic transformation.
- Survival was worse in older patients.
- Prior MPN subtypes had no impact.
Shrestha R, Girl S, Armitage J, Bhatt V. Leukemic transformation in patients with myeloproliferative neoplasms: A population-based retrospective study. [Published online ahead of print June 7, 2017]. Future Oncol. doi:10.2217/fon-2016-0510.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al